Overview

A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Status:
Active, not recruiting
Trial end date:
2021-11-12
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of the combination of parsaclisib and ruxolitinib in subjects with myelofibrosis.
Phase:
Phase 2
Details
Lead Sponsor:
Incyte Corporation